Lumos Diagnostics Holdings Ltd (ASX:LDX) is set to see its point-of-care respiratory test FebriDx made available to a large audience in the United States, through the awarding of a national contract with MediGroup. The FebriDx test provides results within 10 minutes, based on a fingerstick blood sample. Its elevation to a national contract with MediGroup follows a decision from the US Food and Drug Administration (FDA) in July 2023 to clear it for marketing as a product to help diagnose bacterial acute respiratory infection and to differentiate from non-bacterial etiology. The clearance was ba…